Emerging BioPharma - Biotech

Power up your clinical trials

Emerging BioPharma - Biotech
the now and the future of clinical research

Emerging BioPharmas (EBPs) are changing the landscape of drug development by developing a large portion of all innovative new medicines. Here at Kayentis, we understand the unique challenges that EBPs face: as they are active in only a limited number of project developments, with limited resources, the stakes for success are extremely high.

  • Our solutions support EBPs to develop innovative therapies and respond to unmet medical needs
  • Our customized solutions address the complexity of each clinical protocol
  • Our flat organization and flexibility ensure a trustful and efficient collaboration

Your trial, our expertise

“Kayentis is looking forward to partnering with each of our new clients on their journey to successfully bringing their products to market or having their assets acquired. Kayentis’ therapeutic expertise and experience conducting electronic data gathering for patients in clinical trials at global levels bring proven, quality outcomes. We have the reliability and flexibility EBPs require.” Guillaume JUGE, Kayentis CEO




    - Supporting more than 15 EBPs and Biotech companies in recent years
    - Key therapeutic expertise in promising therapies: rare disease, oncology, inflammation/immune disorders...


    - Strong customer service support
    - Reactivity & flexibility
    - Proximity with regional teams focused on your goals
    - Scientific support


    - Our capabilities and ability to customize solutions
    - Configurable products to fit each study requirement

  • Your challenges, our experience